JP2011515478A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515478A5
JP2011515478A5 JP2011501946A JP2011501946A JP2011515478A5 JP 2011515478 A5 JP2011515478 A5 JP 2011515478A5 JP 2011501946 A JP2011501946 A JP 2011501946A JP 2011501946 A JP2011501946 A JP 2011501946A JP 2011515478 A5 JP2011515478 A5 JP 2011515478A5
Authority
JP
Japan
Prior art keywords
inhibitor
antibody
cdr
ser
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011501946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/037953 external-priority patent/WO2009142810A2/en
Publication of JP2011515478A publication Critical patent/JP2011515478A/ja
Publication of JP2011515478A5 publication Critical patent/JP2011515478A5/ja
Pending legal-status Critical Current

Links

JP2011501946A 2008-03-25 2009-03-23 結腸直腸がんを処置または予防するための方法 Pending JP2011515478A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3919708P 2008-03-25 2008-03-25
US61/039,197 2008-03-25
PCT/US2009/037953 WO2009142810A2 (en) 2008-03-25 2009-03-23 Methods for treating or preventing colorectal cancer

Publications (2)

Publication Number Publication Date
JP2011515478A JP2011515478A (ja) 2011-05-19
JP2011515478A5 true JP2011515478A5 (enExample) 2013-03-14

Family

ID=41340744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011501946A Pending JP2011515478A (ja) 2008-03-25 2009-03-23 結腸直腸がんを処置または予防するための方法

Country Status (8)

Country Link
US (1) US20110104256A1 (enExample)
EP (1) EP2259797A2 (enExample)
JP (1) JP2011515478A (enExample)
CA (1) CA2718918A1 (enExample)
CL (1) CL2009000721A1 (enExample)
MX (1) MX2010010480A (enExample)
TW (1) TW200944233A (enExample)
WO (1) WO2009142810A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
CA2730715C (en) 2008-08-04 2013-10-01 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN102292078A (zh) 2008-11-11 2011-12-21 得克萨斯大学体系董事会 哺乳动物雷帕霉素靶蛋白的抑制
EP2396003B1 (en) 2009-02-12 2013-04-17 ArQule, Inc. A composition comprising (-)-trans-3-(5,6-dihydro-4h-pyrrolo [3,2,1-ij] quinolin-1-yl)-4-(1h-indol-3-yl) pyrrolidine-2, 5-dione in combination with sorafenib, sunitinib or erlotinib
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US8580764B2 (en) * 2010-07-01 2013-11-12 Arqule, Inc. Combinational compositions and methods for treatment of cancer
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
EP2611443A2 (en) 2010-09-01 2013-07-10 ArQule, Inc. Methods for treatment of non-small cell lung cancer
WO2013162368A1 (en) * 2012-04-26 2013-10-31 Stichting Vu-Vumc Biomarkers
NL2010276C2 (en) * 2013-02-08 2014-08-11 Stichting Vu Vumc Biomarkers.
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
DK2968281T3 (da) 2013-03-13 2020-11-02 Univ Texas Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
CA2933908C (en) 2013-12-31 2024-01-30 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
JP6210640B2 (ja) * 2014-06-19 2017-10-11 大原薬品工業株式会社 ホリナートカルシウム含有錠
WO2016054055A1 (en) * 2014-09-29 2016-04-07 Board Of Regent, The University Of Texas System Prediction of response to parp inhibitors and combinational therapy targeting c-met and parp1
EP3281016A1 (en) 2015-04-10 2018-02-14 Applied Proteomics Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
SG10201913077QA (en) 2015-08-21 2020-02-27 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
WO2017136671A1 (en) * 2016-02-04 2017-08-10 Chattterjee Bandana Combination therapy for castration-resistant prostate cancer
BR112019007844A2 (pt) 2016-11-02 2019-07-16 Ipsen Biopharm Ltd tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)
JP2017210493A (ja) * 2017-09-08 2017-11-30 大原薬品工業株式会社 ホリナートカルシウム含有錠
CN113164480B (zh) * 2018-11-14 2023-11-28 学校法人金泽医科大学 用于治疗弥漫性胃癌的药物组合物
JP2021036003A (ja) * 2020-12-05 2021-03-04 大原薬品工業株式会社 ホリナートカルシウム含有錠
JPWO2023008462A1 (enExample) * 2021-07-27 2023-02-02

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX337162B (es) * 2001-01-05 2016-02-15 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
EP2316922B1 (en) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
EP2135879A3 (en) * 2002-06-28 2010-06-23 Domantis Limited Ligand
ES2351395T3 (es) * 2003-08-13 2011-02-04 Pfizer Products Inc. Anticuerpos humanos modificados anti-igf-1r.
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
KR20090130156A (ko) * 2004-09-22 2009-12-17 화이자 인코포레이티드 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는 치료 배합물
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
CN101287761A (zh) * 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
US20080299113A1 (en) * 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
WO2007113648A2 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
JP5399900B2 (ja) * 2006-06-30 2014-01-29 メルク・シャープ・アンド・ドーム・コーポレーション Igfbp2インヒビター
WO2008076257A2 (en) * 2006-12-13 2008-06-26 Schering Corporation Treating cancer with anti-igflr antibody 19d12 = sch 717454
CA2722992A1 (en) * 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2011515478A5 (enExample)
JP2011519868A5 (enExample)
JP2019503674A5 (enExample)
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
RU2010120674A (ru) Полностью человеческие анти-vegf-антитела и способы их применения
JP2012247438A5 (enExample)
RU2018123481A (ru) Анти-lag3 антитела и антигенсвязывающие фрагменты
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
JP2014516964A5 (enExample)
US10323090B2 (en) PD1 and/or LAG3 binders
US10544222B2 (en) PD1/CTLA4 binders
AU2016355569B2 (en) CTLA4 binders
WO2019199621A4 (en) Bi-functional molecules to degrade circulating proteins
IL319363A (en) Cervalon ligands and bifunctional compounds containing them
WO2009137378A2 (en) Sequential administration of chemotherapeutic agents for treatment of cancer
JP2011515478A (ja) 結腸直腸がんを処置または予防するための方法
JP2005527222A5 (ja) 中和ヒト抗igfr抗体
JP2014516964A (ja) 治療用抗igf1r合剤
KR20170065466A (ko) 인간vegf-a에 특이하게 강한 결합 친화도 및 인간vegf-b에 교차 반응성을 가진 항-인간vegf 항체
JPWO2021055705A5 (enExample)
US9346846B1 (en) Anti-cancer compounds and methods for treating cancer
WO2025130666A1 (zh) 抗cd93抗体或其抗原结合片段及其应用
AU2018375719A1 (en) Compositions and methods for cancer therapy
NZ752184B2 (en) Antibody specifically binding to pd-1 and functional fragment thereof
NZ752184A (en) Antibody specifically binding to pd-1 and functional fragment thereof